Security
GSK · GSK plc
GSKNYSEotherCurrentCIK 1131399Updated Sep 24, 2026
Name history
GLAXOSMITHKLINE PLC · through May 16, 2022
GSK price & chart
Loading TradingView…
NYSE:GSK on TradingView ↗In the news
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) ↗
Myriad Venture Partners Expands Executive Advisory Board as Enterprise AI Moves Into Production ↗
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK News provided by Samsung Biologics Dec 21, 2025, 17:43 ET Share this article Share to X Share this article Share to X Secures the company's first U.S.-based manufacturing site, stre ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · GBPSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossGBP | 6,289,000,000Source | 2,951,000,000Source | 5,308,000,000Source | 15,621,000,000Source |
| Cash flows from financing activities: | ||||
| Dividends paid | — | — | — | — |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodGBP | -49,000,000Source | -92,000,000Source | 43,000,000Source | -60,000,000Source |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableGBP | -613,000,000Source | 298,000,000Source | -794,000,000Source | -158,000,000Source |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesGBP | 0Source | 6,000,000Source | 1,000,000Source | 0Source |
| AdjustmentsForIncomeTaxExpenseGBP | 1,112,000,000Source | 526,000,000Source | 756,000,000Source | 707,000,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableGBP | 131,000,000Source | -179,000,000Source | -15,000,000Source | 494,000,000Source |
| AdjustmentsForSharebasedPaymentsGBP | 374,000,000Source | 344,000,000Source | 307,000,000Source | 346,000,000Source |
| DividendsPaidOrdinarySharesPerShareGBP/shares | 0.66Source | 0.61Source | 0.58Source | 0.61Source |
| GoodwillGBP | 7,018,000,000Source | 6,982,000,000Source | 6,811,000,000Source | 7,046,000,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesGBP | 1,202,000,000Source | 1,307,000,000Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesGBP | 679,000,000Source | 632,000,000Source | 766,000,000Source | 848,000,000Source |
| OtherAdjustmentsToReconcileProfitLossGBP | -9,000,000Source | -110,000,000Source | -100,000,000Source | -170,000,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP | 241,000,000Source | 226,000,000Source | 197,000,000Source | 202,000,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesGBP | 1,377,000,000Source | — | — | — |
| ProceedsFromIssuingSharesGBP | 15,000,000Source | 20,000,000Source | 10,000,000Source | 25,000,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesGBP | 24,000,000Source | 65,000,000Source | 28,000,000Source | 146,000,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesGBP | 1,637,000,000Source | 1,583,000,000Source | 1,030,000,000Source | 1,115,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseGBP | 9,088,000,000Source | 11,015,000,000Source | 9,385,000,000Source | 8,372,000,000Source |
| Total RevenueGBP | 32,667,000,000Source | 31,376,000,000Source | 30,328,000,000Source | 29,324,000,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | — | — | — | 0.19Source |
| AverageEffectiveTaxRatenumber | 0.15Source | 0.15Source | 0.13Source | 0.13Source |
| BasicEarningsLossPerShareGBP/shares | 1.41Source | 0.63Source | 1.22Source | 3.71Source |
| DeferredTaxExpenseIncomeGBP | -283,000,000Source | -1,026,000,000Source | -865,000,000Source | -784,000,000Source |
| DepreciationAndAmortisationExpenseGBP | 2,314,000,000Source | 2,551,000,000Source | 2,294,000,000Source | 2,147,000,000Source |
| DepreciationRightofuseAssetsGBP | 206,000,000Source | 211,000,000Source | 190,000,000Source | 176,000,000Source |
| DilutedEarningsLossPerShareGBP/shares | 1.39Source | 0.62Source | 1.2Source | 3.66Source |
| EmployeeBenefitsExpenseGBP | 8,772,000,000Source | 8,759,000,000Source | 8,473,000,000Source | 7,693,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesGBP | 390,000,000Source | 347,000,000Source | 321,000,000Source | 314,000,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedGBP | — | 2,000,000Source | 2,000,000Source | 2,000,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedGBP | — | 13,000,000Source | 8,000,000Source | 6,000,000Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesGBP | — | 15,000,000Source | 17,000,000Source | 9,000,000Source |
| FinanceCostsGBP | 701,000,000Source | 669,000,000Source | 792,000,000Source | 879,000,000Source |
| FinanceIncomeGBP | 169,000,000Source | 122,000,000Source | 115,000,000Source | 76,000,000Source |
| GrossProfitGBP | 23,650,000,000Source | 22,328,000,000Source | 21,763,000,000Source | 19,770,000,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillGBP | 888,000,000Source | 317,000,000Source | — | — |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossGBP | 4,000,000Source | -12,000,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsGBP | 1,112,000,000Source | 526,000,000Source | 756,000,000Source | 707,000,000Source |
| InterestExpenseGBP | — | — | — | 912,000,000Source |
| InterestExpenseOnLeaseLiabilitiesGBP | 46,000,000Source | 46,000,000Source | 38,000,000Source | 30,000,000Source |
| OtherOperatingIncomeExpenseGBP | 16,000,000Source | -1,530,000,000Source | -363,000,000Source | -235,000,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansGBP | 170,000,000Source | 218,000,000Source | — | — |
| PostemploymentBenefitExpenseDefinedContributionPlansGBP | 130,000,000Source | 150,000,000Source | — | — |
| ProfitLossAttributableToNoncontrollingInterestsGBP | 573,000,000Source | 376,000,000Source | 380,000,000Source | 665,000,000Source |
| ProfitLossAttributableToOwnersOfParentGBP | 5,716,000,000Source | 2,575,000,000Source | 4,928,000,000Source | 14,956,000,000Source |
| ProfitLossBeforeTaxGBP | 7,401,000,000Source | 3,477,000,000Source | 6,064,000,000Source | 5,628,000,000Source |
| ProfitLossFromOperatingActivitiesGBP | 7,932,000,000Source | 4,021,000,000Source | 6,745,000,000Source | 6,433,000,000Source |
| ResearchAndDevelopmentExpenseGBP | 7,525,000,000Source | 6,401,000,000Source | 6,223,000,000Source | 5,488,000,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodGBP | 1,000,000Source | -3,000,000Source | -5,000,000Source | -2,000,000Source |
| TaxRateEffectOfForeignTaxRatesnumber | -0Source | 0.05Source | 0.03Source | 0.06Source |